NAVITOR
Device
Abbott Laboratories
Total Payments
$2.8M
Transactions
4,571
Doctors
1,666
Companies
1
Payment Trends by Year
| Year | Amount | Transactions | Doctors |
|---|---|---|---|
| 2024 | $2.5M | 3,516 | 1,357 |
| 2023 | $292,541 | 1,055 | 504 |
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Unspecified | $1.6M | 577 | 58.2% |
| Consulting Fee | $356,727 | 91 | 12.7% |
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $331,251 | 69 | 11.8% |
| Food and Beverage | $220,266 | 3,551 | 7.9% |
| Space rental or facility fees (teaching hospital only) | $141,200 | 4 | 5.0% |
| Travel and Lodging | $121,606 | 279 | 4.3% |
Payments by Type
Research
$1.6M
577 transactions
General
$1.2M
3,994 transactions
Research Studies & Clinical Trials
| Study Name | Sponsor | Amount | Doctors |
|---|---|---|---|
| Evaluation of the Navitor Transcatheter Heart Valve in Low and Intermediate Risk Patients Who Have Severe, Symptomatic, Aortic Stenosis Requiring Aortic Valve Replacement | Abbott Laboratories | $1.0M | 0 |
| Envision IDE Study | Abbott Laboratories | $555,186 | 0 |
| Evaluation of the Navitor Transcatheter Heart Valve in Low and Intermediate Risk Patients Who Have Severe, Symptomatic, Aortic Stenosis Requiring Aortic Valve Replacement (ENVISION) | Abbott Laboratories | $73,681 | 0 |
| Envision IDE | Abbott Laboratories | $2,460 | 0 |
| Coronary IVL IDE Study | Abbott Laboratories | $317.70 | 0 |
Top Doctors Receiving Payments for NAVITOR — Page 5
| Doctor | Specialty | Location | Total | Records |
|---|---|---|---|---|
| , MD | Cardiovascular Disease | Philadelphia, PA | $512.61 | 5 |
| , M.D | Interventional Cardiology | Huntsville, AL | $488.36 | 5 |
| , MD | Surgery | Pittsburgh, PA | $483.88 | 13 |
| , M.D | Surgery | San Antonio, TX | $483.55 | 3 |
| , DO | Cardiovascular Disease | Largo, FL | $467.95 | 4 |
| , MD | Thoracic Surgery (Cardiothoracic Vascular Surgery) | Brandon, FL | $467.95 | 4 |
| , M.D | Surgery | Pgh., PA | $462.93 | 15 |
| , M.D | Thoracic Surgery (Cardiothoracic Vascular Surgery) | Doral, FL | $462.61 | 12 |
| , MD | Thoracic Surgery (Cardiothoracic Vascular Surgery) | Philadelphia, PA | $451.98 | 4 |
| , M.D | Internal Medicine | La Jolla, CA | $449.35 | 5 |
| , M.D | Thoracic Surgery (Cardiothoracic Vascular Surgery) | Bradenton, FL | $444.89 | 4 |
| , M.D | Cardiovascular Disease | New Hyde Park, NY | $443.25 | 3 |
| , M.D | Thoracic Surgery (Cardiothoracic Vascular Surgery) | New York, NY | $436.83 | 5 |
| , MS, RN, AGACNP-BC | Acute Care | Bronx, NY | $436.46 | 6 |
| , MD | Cardiovascular Disease | Mineola, NY | $435.99 | 4 |
| , MD | Internal Medicine | Hialeah, FL | $433.82 | 3 |
| , MD | Interventional Cardiology | Hasbrouck Heights, NJ | $429.56 | 7 |
| , M.D | Cardiovascular Disease | New York, NY | $427.02 | 11 |
| , MD | Interventional Cardiology | Miami, FL | $419.14 | 5 |
| , ACNP | Acute Care | Houston, TX | $418.63 | 8 |
| , M.D | Student in an Organized Health Care Education/Training Program | Hackensack, NJ | $416.67 | 6 |
| , M.D | Cardiovascular Disease | La Jolla, CA | $411.56 | 5 |
| , M.D | Student in an Organized Health Care Education/Training Program | Houston, TX | $410.15 | 3 |
| , M.D | Cardiovascular Disease | Philadelphia, PA | $392.81 | 3 |
| , M.D | Interventional Cardiology | La Jolla, CA | $390.82 | 7 |
Ad
Manufacturing Companies
- Abbott Laboratories $2.8M
Product Information
- Type Device
- Total Payments $2.8M
- Total Doctors 1,666
- Transactions 4,571
About NAVITOR
NAVITOR is a device associated with $2.8M in payments to 1,666 healthcare providers, recorded across 4,571 transactions in the CMS Open Payments database. The primary manufacturer is Abbott Laboratories.
Payment data is available from 2023 to 2024. In 2024, $2.5M was paid across 3,516 transactions to 1,357 doctors.
The most common payment nature for NAVITOR is "Unspecified" ($1.6M, 58.2% of total).
NAVITOR is associated with 5 research studies, including "Evaluation of the Navitor Transcatheter Heart Valve in Low and Intermediate Risk Patients Who Have Severe, Symptomatic, Aortic Stenosis Requiring Aortic Valve Replacement" ($1.0M).